DrugPatentWatch Database Preview

Details for Patent: 7,078,412

« Back to Dashboard

Which drugs does patent 7,078,412 protect, and when does it expire?

Patent 7,078,412 protects TUDORZA PRESSAIR and is included in one NDA.

This patent has fifty-five patent family members in thirty-four countries.

Summary for Patent: 7,078,412

Title:	Quinuclidine derivatives and medicinal compositions containing the same
Abstract:	The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds.
Inventor(s):	Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES)
Assignee:	Almirall Prodesfarma AG (Baar, CH)
Application Number:	11/116,777
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 7,078,412

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Astrazeneca Pharms	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes			Y	Y		TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS

Foreign Priority and PCT Information for Patent: 7,078,412

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Spain	9901580	Jul 14, 1999

Non-Orange Book US Patents Family Members for Patent 7,078,412

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,196,098	Quinuclidine derivatives and medicinal compositions containing the same
7,214,687	Quinuclidine derivatives and medicinal compositions containing the same
7,358,260	Quinuclidine derivatives and medicinal compositions containing the same
6,750,226	Quinuclidine derivatives and their use as muscarinic M3 receptor ligands

International Patents Family Members for US Patent 7,078,412

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	029760
Austria	235492
Australia	2005202144
Australia	6433000